Clinical Trials

Among 2 analysts covering Mistras Group (NYSE:MG), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Mistras Group had 5 analyst reports since February 23, 2019 according to SRatingsIntel. Sidoti maintained Mistras Group, Inc. (NYSE:MG) rating on Tuesday, March 12. Sidoti has “Buy” rating and $21 target. Canaccord Genuity maintained Mistras […]

Scopia Capital Management Lp decreased its stake in Gw Pharmaceuticals Plc (GWPH) by 9.55% based on its latest 2018Q4 regulatory filing with the SEC. Scopia Capital Management Lp sold 142,109 shares as the company’s stock rose 45.17% with the market. The hedge fund held 1.35 million shares of the major pharmaceuticals company at the end […]

Arcadia Investment Management Corp increased its stake in Procter And Gamble Co (PG) by 320.58% based on its latest 2018Q4 regulatory filing with the SEC. Arcadia Investment Management Corp bought 5,873 shares as the company’s stock rose 6.30% with the market. The institutional investor held 7,705 shares of the package goods and cosmetics company at […]

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Friday, ValuEngine reports. A number of other research firms also recently issued reports on ZYNE. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $26.00 target price on shares of […]

SMITHS FALLS, ON, May 7, 2019 /CNW/ – Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NYSE: CGC) is pleased to introduce Spectrum Therapeutics, a new global brand that will encompass all of the Company’s ongoing commercial medical and clinical research operations including Spectrum Cannabis, Canopy Health Innovations (CHI), and the most recent addition […]

Intec Pharma (NASDAQ:NTEC) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation. Profitability This table compares Intec Pharma and Affimed’s net margins, return on equity and return on […]

Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.02, MarketWatch Earnings reports. ZYNE opened at $15.50 on Friday. Zynerba Pharmaceuticals has a one year low of $2.75 and a one year high […]

Intec Pharma (NASDAQ:NTEC) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability. Volatility and Risk Intec Pharma has a beta of 0.29, suggesting that its stock price […]

Worldwide sales of the controlled substances closed in on a valuation of US$ 67,000 Mn in 2018, and are projected to record a Y-o-Y growth at 3.5% in 2019, according to a new Fact.MR study. The study opines that depressants and stimulants have been top-selling class of drugs in the controlled substances market, however gains […]

Zynerba Pharmaceuticals (NASDAQ:ZYNE) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, April 30th, ValuEngine reports. A number of other research firms have also recently weighed in on ZYNE. Roth Capital initiated coverage on Zynerba Pharmaceuticals in a report […]